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ABSTRACT
Objectives Predicting mortality in middle-aged HIV-
infected (HIV+) women on antiretroviral therapies (ART) is 
important for understanding the impact of HIV infection. 
Several health indices have been used to predict mortality 
in women with HIV infection. We evaluated: (1) an HIV 
biological index, Veterans Aging Cohort Study (VACS); (2) 
a physical index, Fried Frailty Index (FFI); and (3) a mental 
health index, Center for Epidemiologic Studies-Depression 
(CES-D). Proportional hazards regression analyses were 
used to predict death and included relevant covariates.
Design Prospective, observational cohort.
Setting Multicentre, across six sites in the USA.
Participants 1385 multirace/ethnic ART-experienced 
HIV+ women in 2005.
Primary and secondary outcomes All deaths, AIDS 
deaths and non-AIDS deaths up to ~8 years from baseline.
Results Included together in one model, VACS Index 
was the dominant, significant independent predictor of 
all deaths within 3 years (HR=2.20, 95% CI 1.83, 2.65, 
χ2=69.04, p<0.0001), and later than 3 years (HR=1.55, 
95% CI 1.30, 1.84, χ2=23.88, p<0.0001); followed by FFI 
within 3 years (HR=2.06, 95% CI 1.19, 3.57, χ2=6.73, 
p=0.01) and later than 3 years (HR=2.43, 95% CI 1.58, 
3.75, χ2=16.18, p=0.0001). CES-D score was not 
independently associated with mortality.
Conclusions and relevance This is the first simultaneous 
evaluation of three common health indices in HIV+ adults. 
Indices reflecting physical and biological ageing were 
associated with death.
InTroducTIon
HIV infection continues as a major global 
health issue affecting approximately 
36 million people worldwide. HIV infection 
has evolved from a fatal infection to a treatable, 
chronic condition of ageing,1 2 accompanied 
by multiple morbidities and rising healthcare 
costs. The North American AIDS Cohort 
Collaboration on Research and Design 
observed that life expectancy of HIV-infected 
(HIV+) adults increased from 36 to 51 years 
between 2000 and 2007,3 primarily due to 
treatment advances. In 2015, over half of 
HIV+ Americans are ≥50 years old.3 There-
fore, HIV infection may prove to represent 
a modern-day phenomenon of achieving 
healthy old age accompanied by improved 
longevity.
Predicting death in chronic HIV infec-
tion may assist in the design of interventions 
to understand, prevent, cure or minimise 
age-related impairments, improve health 
and increase lifespan. Several health indices 
predict death in adults with HIV infection—
the Veterans Aging Cohort Study (VACS) 
Index; Fried Frailty Index (FFI); and the 
Center for Epidemiologic Studies-Depres-
sion (CES-D) score. These indices represent 
biological, physical and mental health vulner-
abilities that worsen with age. The only 
HIV-specific mortality index is the VACS 
Index, which has been reproduced in North 
American and European patient populations 
including highly active antiretroviral therapy 
(HAART) users in the Women’s Interagency 
HIV Study (WIHS).4 5 The VACS Index creates 
a clinical HIV mortality risk score by summing 
preassigned points for age, routinely moni-
tored indicators of HIV disease and general 
Strengths and limitations of this study
 ► Longitudinal cohort study with follow-up of almost 
10 years.
 ► Well-phenotyped White, African-American and 
Latina HIV-infected women.
 ► Reputable standardised and validated physical, 
biological and mental health indices.
 ► Somewhat limited generalisability since a survivor 
sample of urban women with strong, consistent 
research study-related HIV care and social support.
 ► Health indices and mortality were examined at 
midlife, a period when risk of death is low.
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indicators of organ system function.5 6 The FFI is most 
commonly used when describing ageing in both general 
and HIV+ populations.7 8 Frailty is a common comor-
bidity of HIV infection, observed even during middle 
age.4 9 The FFI includes measures of gait speed, handgrip 
strength, body weight loss, physical activity, and exhaus-
tion and predicts death.10–12 The CES-D score measures 
mental health13 and has been independently associated 
with mortality, particularly among women with HIV infec-
tion on HAART in the WIHS.4
The objective of our analyses was to evaluate, among 
HIV+ women, the association of the aforementioned, 
frequently used health indices, VACS, FFI and CES-D, 
with death (both AIDS related and non-AIDS related). All 
indices were measured in midlife (average age 39 years) in 
our analyses and evaluated for prediction of mortality for 
up to ~8 years. This follow-up period was further broken 
down into short-term (within 0–3 years) and long-term 
(>3 to ~8 years) deaths, since studies show that predic-
tion of death may vary depending on the exposure being 
evaluated in relation to more immediate precipitating 
diseases or conditions versus chronic outcomes.
MeThods
study population
WIHS is a prospective, observational cohort suitable to study 
the intersection of HIV infection and ageing. WIHS partic-
ipants enrolled at six sites (Bronx/Manhattan, Brooklyn, 
Chicago, Los Angeles, San Francisco and Washington, 
DC); methods and baseline cohort characteristics have 
been described previously.14 Participants have visits every 6 
months, which include an extensive face-to-face interview 
by trained interviewers, medical examinations and labo-
ratory specimen collection. Written informed consent was 
provided by all WIHS participants via human subject proto-
cols that were approved by institutional review committees 
at each affiliated institution (Albert Einstein College of 
Medicine and Montefiore Medical Center Institutional 
Review Board, #03-07-174; Cook County Bureau of Health 
Services Institutional Review Board, #15–084; Georgetown 
University Institutional Review Board, Protocol #1993–077; 
State University of New York-Downstate Medical Center 
Institutional Review Board, #266921; University of California 
San Francisco Committee on Human Research, #1003720; 
and University of Southern California Institutional Review 
Board, HS-944027.)
Of the HIV+ women actively enrolled in 2005,  1395 
completed an assessment of the FFI. Of these, 1385 women 
were antiretroviral therapy (ART)-experienced and had 
measures of both VACS Index and CES-D. These women 
are included in the current analyses.
Inclusion criteria
Women included in these analyses are HIV+ members of 
the WIHS cohort who had to have adequately completed all 
indices (VACS, FFI, CES-D) in 2005 for evaluation in associ-
ation with mortality.
Primary outcome
Mortality over the ~8 years, 2005–2013 (also subcat-
egorised into 0–3 and >3 to ~8 years), subsequent to 
measurement of the health indices, was the primary 
outcome. The US National Death Index identified 
numbers and causes of death from 1 January 2005 
through 31 December 2013. Causes of death were 
subdivided into AIDS and non-AIDS deaths based on 
consensus panels comprised of WIHS investigators15 
(see figure 1). AIDS deaths included: pneumonia, 
progressive multifocal leukoencephalopathy (PML), 
pneumocystis pneumonia (PCP), wasting syndrome, 
central nervous system (CNS) lymphoma, candida, 
cytomegalovirus (CMV), Cryptococcus, toxoplasmosis, 
tuberculosis (TB)/mycobacterium, cervical cancer, 
pulmonary hypertension, dementia/neurologic, renal 
failure, multiorgan failure and pancreatitis. Non-AIDS 
deaths included: non-AIDS-related malignancy, gastroin-
testinal, trauma, drug/alcohol overdose, heart disease, 
lung disease, liver disease, kidney disease, neurologic/
stroke, haemorrhage, pneumonia, psychiatric, surgical 
complication or pregnancy complication. For some, 
cause of death could not be classified as AIDS or 
non-AIDS, thus the sum of these two subcategories is 
less that the total number of deaths during the follow-up 
period.
Primary predictors of death
There were three primary predictors of interest: VACS 
Index, FFI and CES-D score. The VACS Index facilitates 
a mortality risk score created by summing preassigned 
points for age, routinely monitored indicators of HIV 
disease (CD4 count and HIV-1 RNA) and viral hepa-
titis C infection (HCV); and general indicators of organ 
system injury including haemoglobin, FIB-4 and esti-
mated glomerular filtration rate, eGFR (mL/min). We 
calculated eGFR based on the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation.16 The 
VACS Index has a maximum score of 164.
The FFI was defined using well-described criteria.7 
A woman was classified as frail if she exhibited three or 
more of five characteristics: (1) impaired mobility, (2) 
reduced grip strength, (3) physical exhaustion, (4) unin-
tentional weight loss and (5) low physical activity. At each 
site, mobility was measured using a 3–4 m timed gait test, 
and impaired mobility was defined as the lowest quintile 
of performance among HIV negatives. Similarly, grip 
strength was measured using a dominant handheld dyna-
mometer with maximum force; reduced grip strength was 
the lowest quintile of performance among HIV negatives. 
Physical exhaustion was a ‘Yes’ to the question: ‘During 
the past four weeks, as a result of your physical health, 
have you had difficulty performing your work or other 
activities (for example, it took extra efforts)?’ Low phys-
ical activity was a ‘Yes’ to ‘Does your health now limit 
you in vigorous activities, such as running, lifting heavy 
objects, or participating in strenuous sports?’ Uninten-
tional weight loss was a ‘Yes’ to: ‘Since your last visit, have 
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you had unintentional weight loss of at least 10 pounds?’ 
If at least three components were available, the total out 
of 3 (or 4) was calculated.
The 20-item CES-D is a depressive symptom screening 
tool comprised of 20 items and totalling 60 points. A cut 
point of 16 was used to denote a symptom burden of clin-
ical relevance.17
statistical analyses
We used single variable and multivariable proportional 
hazards models to address the questions of which indices 
(of FFI, VACS or CES-D), when measured at midlife in this 
sample of HIV+ women, best predicted AIDS, non-AIDS 
and all deaths. Concordance statistics (C-statistics) were 
also calculated. The C-statistic for time-to-event outcomes 
is equivalent to the area under the receiver operating 
characteristic curve for standard binomial outcomes 
(range 0.5–1.0). It describes the probability of death asso-
ciated with a higher health index score or combination of 
higher health index scores in a randomly selected partici-
pant compared with those who do not die.18 
Covariates found to be significantly associated with 
mortality were included in these analyses.4 These covari-
ates included race/ethnicity, education, smoking, annual 
income, alcohol drinking, intravenous drug use (IDU) 
history, body mass index, prior AIDS-defining illness, 
pneumonia, cancer, diabetes and hypertension. Methods 
for determining HIV and HCV infection status, AIDS 
diagnosis, CD4 cell count, HIV viral load, ART use and 
IDU were described previously.9 
We refit models (1) restricting follow-up time to the 
first 3 years after measurement (ie, censoring at 3 years), 
and (2) starting follow-up time at 3 years after the health 
indices measurements (ie, truncating prior to 3 years). 
In addition, the interaction between FFI and CES-D was 
considered. Results of proportional hazards regression 
models are presented as HRs with 95% CI. The χ2 statistic 
is also presented to facilitate comparison of strength of 
association between models since the HR scale of each 
ageing vulnerability index is not the same. Data anal-
yses were accomplished using SAS V.9.4. C-statistics were 
calculated using STATA V.12.1.
Modified VACS and CES-D Indices. While not reported 
here, as a sensitivity analysis, we reran the statistical models 
using a modified VACS Index and a modified CES-D. Our 
modified VACS Index did not include VACS age groups 
in the derivation of total points due to the younger age of 
our sample (VACS Index lowest age group is <50 years). 
Thus, a maximum score of 136 was attainable. We then 
adjusted for age as age decades that reflected our sample 
as a separate covariate in multivariate analyses. Our modi-
fied CES-D score resulted from excluding two CES-D 
symptoms that overlap with the FFI. The excluded CES-D 
Figure 1 WIHS participants with the VACS Index, FFI and CES-D measured in 2005 and follow-up over approximately 8 
years. ART, antiretroviral therapies; CES-D, Center for Epidemiologic Studies-Depression; FFI, Fried Frailty Index; HIV+, HIV-
infected; VACS, Veterans Aging Cohort Study; WIHS, Women’s Interagency HIV Study.  
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symptoms were ‘this past week I could not get going’ 
(overlaps with low physical activity in the FFI) and ‘this 
past week everything was an effort’ (overlaps with exhaus-
tion in the FFI).
resulTs
Data were available for all indices on 1385 HIV+ women 
(average age 42.6±8.8 years) who reported history of ART 
use. The average VACS score was 28.9±19.4 (possible 
range 0–164); prevalence of frailty (defined as FFI=3–5) 
was 17.5%; and 39.1% had a CES-D score of at least 16 
points indicating a clinically relevant depressive symptom 
burden. With regard to calculating the FFI of 1385 women, 
1166 (84.2%) had no missing components, 94 (6.8%) had 
one missing component and 125 (9.0%) had two missing 
components. The three indices, as well as individual VACS 
components, demographic/health behaviour, infec-
tious disease, chronic ageing-related disease variables, 
number and types of deaths are presented in table 1. The 
crude HR (95% CI) for all deaths by health indices and 
demographic/health behaviours, infectious diseases and 
chronic ageing-related disease variables are presented in 
table 2.
C-statistics. When evaluated in multivariable models, 
worse (higher) FFI, VACS and CES-D indices were 
each significantly associated with a more rapid onset of 
mortality, additive to higher age and several other covari-
ates based on C-statistics (table 3). As a single index 
added on to demographics, the VACS Index performed 
best for all and AIDS deaths; however, the FFI was best 
for non-AIDS deaths. The C-statistics were qualitatively 
higher for AIDS deaths, reaching 0.89 with demographics 
and the VACS Index in the model (and remaining at 
0.89 in the full model), compared to the C-statistics for 
non-AIDs deaths which reached 0.80 with VACS and 
FFI in the model (and only improving to 0.81 in the full 
model).
Using multivariable proportional hazards regression 
models that included all indices, we separately evalu-
ated all deaths up to ~8 years from baseline (table 4) and 
subdivided by timing of death (short term, 0–3 years vs 
long term, >3 to ~8 years from baseline, table 5). We also 
modelled AIDS and non-AIDS deaths separately over the 
same time periods. Over the entire follow-up period, FFI 
was a stronger predictor of non-AIDS deaths than was 
the VACS Index, while VACS was a stronger predictor of 
AIDS deaths than was FFI. Yet, all HRs were significant for 
both indices. CES-D was not an independently significant 
predictor of death.
All deaths
When considering all deaths, within the first 3 years after 
baseline measurement (table 5A) the VACS Index was 
the dominant, significant independent predictor of all 
deaths (HR=2.20, 95% CI 1.83, 2.65, χ2=69.04, p<0.0001), 
followed by FFI (HR=2.06, 95% CI 1.19, 3.57, χ2=6.73, 
p=0.01). For deaths occurring later than 3 years after 
Table 1 Baseline characteristics of HIV+ WIHS participants 
who are not ART naïve
Variables N (%) or mean ± SD
Indices
 FFI
  0–2 points 1143 (82.5)
  3–5 points 242 (17.5)
VACS Index score
  0–164 points 28.9±19.4
CES-D score >16 points
  No 844 (60.9)
  Yes 541 (39.1)
Outcomes
All deaths
  3 years or less 73 (5.3)
  >3–8 years 111 (8.0)
AIDS deaths*
  3 years or less 39 (2.8)
  >3–8 years 35 (2.5)
Non-AIDS deaths*
  3 years or less 32 (2.3)
  >3–8 years 45 (3.2)
HIV variables
CD4 count (cells/mm3)
  >500 554 (40.0)
  200–499 614 (44.3)
  <200 217 (15.7)
Viral load (copies/mL)
  <500 820 (59.2)
  500–100 000 510 (36.8)
  >100 000 55 (4.0)
Haemoglobin (g/dL)
  >14 209 (15.1)
  12–13.9 743 (53.6)
  10–11.9 362 (26.1)
  <10 71 (5.1)
FIB4
  <1.45 1018 (73.5)
  1.45–3.25 280 (20.2)
  >3.25 87 (6.3)
eGFR (mL/min)
  >60 1277 (92.2)
  45–59.9 71 (5.1)
  30–44.9 15 (1.1)
  <30 22 (1.6)
  Hepatitis C coinfection 298 (21.5)
Demographic variables
Continued
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baseline measures (table 5B), the relative influence of 
the VACS Index decreased (HR=1.55, 95% CI 1.30, 1.84, 
χ2=23.88, p<0.0001), and the FFI increased (HR=2.43, 
95% CI 1.58, 3.75, χ2=16.18, p=0.0001).
AIds deaths
Within 3 years after baseline (table 5C), VACS Index was 
the only statistically significant independent predictor 
(HR=3.33, 95% CI 2.56, 4.33, χ2=80.32, p<0.0001) of 
AIDS deaths; for AIDS death after 3 years (table 5D), 
both VACS Index (HR=1.75, 95% CI 1.31, 2.35, χ2=13.97 
p=0.0002) and FFI (HR=3.38, 95% CI 1.55, 7.37, χ2=9.40, 
p=0.002) were independently significant.
non-AIds deaths
FFI was the most significant predictor of non-AIDS 
death both within (table 5E) (HR=3.37, 95% CI 1.53, 
7.40, χ2=9.15, p=0.003) and later (table 5F) than 3 years 
post baseline (HR=3.20, 95% CI 1.66, 6.20, χ2=11.95, 
p=0.0005). The VACS Index predicted death later than 3 
years (HR=1.41, 95% CI 1.07, 1.86, χ2=5.84, p=0.016), but 
was not quite as robust as the FFI.
CES-D score was not an independently significant (at 
p<0.05) predictor in any AIDS or non-AIDS death model 
after adjusting for FFI and VACS Index. Also of note, 
inclusion of ART-naïve participants (n=54, for a total N 
of 1439), the use of modified VACS and CES-D Indices 
or including an interaction term for FFI × CES-D as 
described in the Methods section in the regression model 
did not change our findings.
dIscussIon
We systematically evaluated the ability of three common 
indices representing physical, biological and mental 
health status to predict mortality in women with HIV 
infection. These indices—VACS, a biological HIV index; 
the FFI, a physical index; and the CES-D, a mental health 
index—were evaluated concurrently in association with 
mortality over approximately 8 years (and repeated for 
0–3 and >3 to ~8 years) among women with HIV infec-
tion. Overall, based on comparative χ2 and C-statistics, 
Variables N (%) or mean ± SD
  Average age (years, mean ± 
SD)
42.6±8.8
Race/ethnicity
  White 324 (23.4)
  Black 806 (58.2)
  Others 255 (18.4)
Education
  <High school 536 (38.7)
  >High school 847 (61.2)
  Mission 2 (0.1)
Smoking history
  Not current smoking 786 (56.8)
  Current smoking 599 (43.2)
Income
  <$12 000 669 (48.3)
  >$12 000 668 (48.2)
  Missing 48 (3.5)
Current alcohol drinking
  Abstainer/none 743 (53.6)
  Low 490 (35.4)
  Moderate 129 (9.3)
  High 23 (1.7)
BMI, kg/m2
  BMI<30 916 (66.1)
  BMI>30 (obesity) 461 (33.3)
  Missing 8 (0.6)
Current ART use
  No 400 (28.9)
  Yes (HAART) 984 (71.0)
  Missing 1 (0.1)
Prior AIDS-defining illness
  No 802 (57.9)
  Yes 583 (42.1)
Injection drug use ever
  Yes 305 (22.0)
  No 1071 (77.3)
  Missing 9 (0.6)
Prior pneumonia
  No 1080 (78.0)
  Yes 305 (22.0)
Current/prior hypertension
  No 964 (69.6)
  Yes 421 (30.4)
History of diabetes
  No 1195 (86.3)
Table 1 Continued 
Continued
Variables N (%) or mean ± SD
  Yes 190 (13.7)
Prior cancer diagnosis
  No 1220 (88.1)
  Yes 165 (11.9)
*For some deaths, cause of death could not be classified as AIDS/
non-AIDS, thus the numbers of AIDS + non-AIDS deaths do not 
sum to total deaths.
ART, antiretroviral therapies; BMI, body mass index; CES-D, Center 
for Epidemiologic Studies-Depression; eGFR, estimated glomerular 
filtration rate; FFI, Fried Frailty Index; HAART, highly active 
antiretroviral therapy; HIV+, HIV-infected; VACS, Veterans Aging 
Cohort Study; WIHS, Women’s Interagency HIV Study.
Table 1 Continued 
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the VACS Index was the strongest predictor of death, 
particularly of AIDS-related deaths and early deaths 
within 3 years after index assessments. The FFI was addi-
tively informative, a better predictor of non-AIDS deaths 
than the VACS and a relatively more important predictor 
of deaths from 3 to ~8 years after index assessments.
First published in 2003, the FFI has been a useful 
construct by which to predict poor quality of life, cogni-
tive impairment, dementia and death.19 Ten years later, 
the first report on a validated VACS Index specific for 
those with HIV infection was published.5 The VACS 
Index has, since then, been used to predict mortality in 
HIV-infected and uninfected populations and has been 
associated with the FFI.6 In the WIHS, the VACS Index 
and CES-D score considered together have been inde-
pendently reported to predict mortality over a 5-year 
period.4 Here we show that with addition of the FFI, these 
relationships change.
The FFI predicts death, particularly among elderly 
(65 years and older).10 More recently, the FFI has been 
measured in younger adult populations who may be at risk 
for premature or earlier ageing, such as those with HIV 
infection.6 20 These studies have shown that adults with 
HIV infection, even in midlife, experience a prevalence 
of frailty equivalent to, and greater than, that observed 
in more elderly adults.4 9 The reason for this early mani-
festation of the frailty phenotype may be a consequence 
of HIV infection itself, including suboptimal medication 
and control of infection early on, comorbid diseases 
(infectious or non-infectious)4 21 and/or other lifestyle 
habits that may be common among those with HIV 
infection, such as smoking and substance use.11 While 
interesting, FFI fluctuations cannot be addressed in these 
analyses, but will be in the future with the reinitiation of 
Table 2 Proportional hazards models of time to all deaths by FFI, VACS Index, CES-D, age group and potential confounders 
among HIV+ women who are not ART naïve.
Variable Crude HR (95% CI) χ2 p Value
Univariate analyses of indices
  VACS score (0–164), per 20 points 2.20 (1.98 to 2.45) 214.6 <0.0001
  FFI 3–5 vs 0–2 3.92 (2.92 to 5.26) 83.2 <0.0001
  CES-D (<16 vs >16) 2.07 (1.55 to 2.77) 24.0 <0.0001
 Univariate analyses of potential confounders
  Age per decade 1.62 (1.38, 1.89) 36.14 <0.0001
  Race/ethnicity 8.95 (2 df) 0.011
  White versus black 0.55 (0.37, 0.83) 8.02 0.005
  Others versus black 0.74 (0.49, 1.11) 2.15 0.140
  Education >high school versus <high school 0.68 (0.51, 0.90) 6.96 0.008
  Smoking (current vs no) 3.41 (2.49, 4.69) 57.5 <0.0001
  Income (<$12 000 vs >$12 000) 2.03 (1.49, 2.77) 19.8 <0.0001
  Drinking 27.25 (3 df) <0.0001
  Low versus abstainer/none 0.59 (0.42, 0.84) 8.59 0.003
  Moderate versus abstainer/none 1.27 (0.82, 1.98) 1.14 0.290
  High versus abstainer/none 3.48 (1.76, 6.87) 12.9 0.0003
  BMI, kg/m2 (>30 vs <30) 0.57 (0.41, 0.81) 10.2 0.001
ART, antiretroviral therapies; BMI, body mass index; CES-D, Center for Epidemiologic Studies-Depression; df, degrees of freedom; FFI, Fried 
Frailty Index; HIV+, HIV-infected; VACS, Veterans Aging Cohort Study.
Table 3 Concordance statistics from proportional hazards 
models for health indices used to predict death among HIV+ 
women who were ART-experienced
Variables All deaths
AIDS 
deaths
Non-AIDS 
deaths
  CES-D + VACS Index 
+ FFI + demographics*
0.83 0.89 0.81
  VACS Index + FFI + 
demographics
0.83 0.89 0.81
  VACS Index + CES-D 
+ demographics
0.82 0.89 0.78
  FFI + CES-D + 
demographics
0.78 0.80 0.80
  VACS Index + 
demographics
0.81 0.89 0.77
  FFI + demographics 0.77 0.78 0.80
  CES-D + 
demographics
0.75 0.77 0.75
  Demographics only* 0.74 0.74 0.76
*Demographic variables included were: age, body mass index, 
race/ethnicity, income, education, cigarette smoking and alcohol 
use.
ART, antiretroviral therapies; CES-D, Center for Epidemiologic 
Studies-Depression; FFI, Fried Frailty Index; HIV+, HIV-infected; 
VACS, Veterans Aging Cohort Study.
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FFI assessments in the WIHS in Fall 2015. As the FFI is a 
marker of the slower process of physical ageing, it may 
continue to be more strongly associated with non-AIDS 
and later deaths as was seen in this analysis.
The CES-D was significantly associated with death in 
models that did not adjust for VACS and FFI (HR=2.07, 
95% CI 1.55, 2.7, p<0.0001, χ2=24.0 in table 2); however, it 
was not associated with death once VACS and FFI indices 
were included in the same model. Several studies that do 
not consider FFI and/or VACS, including those from the 
WIHS, have found CES-D to be a significant ‘indepen-
dent’ predictor of mortality.4 15 22–25 This study calls into 
question whether CES-D is a surrogate for other vulner-
abilities rather than being independently and causally 
associated with death. Other studies or analyses of CES-D 
in relation to death tend to not include other health 
indices in their models or only include VACS.4 It should 
be noted that modifying the CES-D to exclude two items 
potentially overlapping with the FFI (low physical activity 
and exhaustion) did not change the failure of CES-D to be 
significant in the multivariate models (data not shown).
Evaluating these health indices in middle-aged HIV+ 
women (the average age of infected women today) is 
important to understanding the impact of HIV infection 
on mortality over the life course. This approach has been 
shown for other diseases of later life.26 Midlife physical, 
biological and/or mental health indicators against the 
background of HIV infection may be associated with 
earlier death.
Why are multidimensional health indices associated 
with mortality in adults with HIV infection? Throughout 
adult life, HIV infection is synergistic with adverse ageing 
influences on the immune, vascular, reproductive and 
central nervous systems, thereby intensifying the ageing 
process.27 28 In our previous cross-sectional analysis of the 
FFI, we showed that the FFI is associated with infectious, 
demographic, chronic disease, and biological factors, 
including individual components of the VACS Index,4 
lending support to this observation.
We chose to assess deaths occurring within 3 years 
versus those occurring >3 years after the indices were 
measured. Studies in HIV-uninfected populations have 
shown that deaths occurring within a short period of 
time (eg, 3 years) tend to be those due to more rapid 
biological triggers of death such as infections (eg, HIV, 
pneumonia) or other acute illnesses, while longer term 
deaths reflect delayed consequences of deteriorating 
biological and physical health.29 Non-AIDS deaths were 
predicted by FFI, whether those deaths occurred within 
versus later than 3 years. VACS was more significant for 
AIDS deaths and deaths occurring within 3 years. Notably, 
both VACS and FFI were stronger predictors of death (all, 
AIDS, non-AIDS) than age and other variables considered 
in the multivariable models reflecting that these indices, 
more than age, carried the consequences of deteriorating 
biological and physical health.
Some limitations of our approach may be that the VACS 
Index was specifically designed and statistically weighted T
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to predict mortality in HIV+ persons, and that the FFI 
was designed to be descriptive of a clinically recognis-
able phenotype. Therefore, the VACS Index may be 
expected to have more explanatory power in multivar-
iate analyses of HIV-related survival. Furthermore, other 
health indices  also predict mortality.30 31 The VACS, FFI 
and CES-D health indices were selected because they are 
typically reported in the literature as being predictive of 
death in HIV+ samples. The point of our analyses was not 
to identify the best mortality index de novo, but rather to 
systematically compare the three health indices that have 
been reported in the literature. An additional limitation 
of these health indices, particularly the FFI, is the blatant 
lack of standardisation across studies. Our goal in these 
analyses, as aforementioned, was to harmonise the WIHS 
FFI with that of another large HIV cohort study in the 
USA—the Male AIDS Cohort Study. This will facilitate our 
future of working together and comparing the natural 
history of frailty among those with HIV infection by sex 
and gender. Finally, the WIHS is a prospective cohort 
study of women (and for these analyses, HIV+ women 
who are ART-experienced), with a defined demographic 
profile (see table 1). This limits generalisability to other 
groups with and without HIV infection.
Ageing with HIV infection is associated with geriatric 
morbidities or syndromes, including frailty and other 
health indices denoting vulnerability;32 however, these 
ageing morbidities often occur earlier among those with 
HIV infection compared with uninfected individuals.33–36 
The question is whether HIV infection leads to more 
severe ageing phenotypes, or accelerates their onset 
leading to earlier age of death.37 These analyses show that 
two health indices, the VACS (biological) index and the 
FFI (physical), independently predict mortality in middle-
aged women with HIV infection; in particular, VACS 
predicted AIDS death while FFI predicted non-AIDS 
death. Inclusion of CES-D, a depressive symptom scale, 
was not independently informative once both the biolog-
ical and physical health indices were considered. This is 
the first published report on the simultaneous evaluation 
of these important indices in association with mortality in 
women with HIV infection. These analyses point to the 
importance of designing interventions to address compo-
nents of multifaceted indices in the hopes of extending 
the lifespan of patients living with chronic HIV.
Table 5 Multivariable proportional hazards models of time to all deaths, AIDS deaths and non-AIDS deaths within 3 years 
versus greater than 3 years by VACS Index, FFI, CES-D and age among HIV+ women who were ART-experienced.
Variable
A. All deaths within 3 years after FFI visit B. All deaths later than 3 years after FFI visit
χ2
Multivariate-adjusted 
HR* (95% CI) p Value χ2
Multivariate-adjusted 
HR* (95% CI) p Value
VACS Index per 20 points 69.04 2.20 (1.83 to 2.65) <0.0001 23.88 1.55 (1.30 to 1.84) <0.0001
FFI (3–5 vs 0–2 points) 6.73 2.06 (1.19 to 3.57) 0.01 16.18 2.43 (1.58 to 3.75) 0.0001
CES-D (<16 vs ≥16 points) 1.01 1.32 (0.77 to 2.28) 0.31 0.11 1.07 (0.71 to 1.62) 0.74
Age per decade 0.09 1.05 (0.77 to 1.42) 0.76 3.24 1.26 (0.98 to 1.61) 0.07
C. AIDS deaths within 3 years or less after 
FFI visit
D. AIDS deaths later than 3 years after FFI 
visit
χ2
Multivariate-adjusted 
HR* (95% CI) p Value χ2
Multivariate-adjusted 
HR* (95% CI) p Value
VACS Index per 20 points 80.32 3.33 (2.56, 4.33) 0.0000 13.97 1.75 (1.31 to 2.35) 0.0002
FFI (3–5 vs 0–2 points) 0.88 1.45 (0.67, 3.14) 0.34 9.40 3.38 (1.55 to 7.37) 0.002
CES-D (<16 vs ≥16 points) 1.96 1.73 (0.80, 3.73) 0.17 0.81 1.43 (0.65 to 3.14) 0.37
Age per decade 2.42 0.72 (0.47, 1.09) 0.12 0.09 0.93 (0.58 to 1.50) 0.77
E. Non-AIDS deaths within 3 years or less 
after FFI visit
F. Non-AIDS deaths later than 3 years after 
FFI visit
χ2
Multivariate-adjusted 
HR* (95% CI) p Value χ2
Multivariate-adjusted 
HR* (95% CI) p Value
VACS Index per 20 points 0.80 1.16 (0.83 to 1.62) 0.37 5.84 1.41 (1.07 to 1.86) 0.016
FFI (3–5 vs 0–2 points) 9.15 3.37 (1.53 to 7.40) 0.003 11.95 3.20 (1.66 to 6.20) 0.0005
CES-D (<16 vs ≥16 points) 0.15 1.17 (0.54 to 2.54) 0.70 0.60 0.77 (0.40 to 1.48) 0.44
Age per decade 7.43 1.90 (1.20 to 3.02) 0.006 1.44 1.26 (0.86 to 1.84) 0.23
*Multivariate models included race/ethnicity; education less than or equal to versus greater than high school; smoking current versus no; 
income less than versus greater than or equal to $12 000 annually; alcohol use: low, moderate or high versus none; and body mass index <30 
vs >30 kg/m2.
ART, antiretroviral therapies; CES-D, Center for Epidemiologic Studies-Depression; FFI, Fried Frailty Index; HIV+, HIV-infected; VACS, 
Veterans Aging Cohort Study.
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